Display options
Cite
Castillo PM, de la Mata M, Casula MF, et al. PEGylated versus non-PEGylated magnetic nanoparticles as camptothecin delivery system. Beilstein J Nanotechnol. 2014;5:1312-9doi: 10.3762/bjnano.5.144.
Castillo, P. M., de la Mata, M., Casula, M. F., Sánchez-Alcázar, J. A., & Zaderenko, A. P. (2014). PEGylated versus non-PEGylated magnetic nanoparticles as camptothecin delivery system. Beilstein journal of nanotechnology, 51312-9. https://doi.org/10.3762/bjnano.5.144
Castillo, Paula M, et al. "PEGylated versus non-PEGylated magnetic nanoparticles as camptothecin delivery system." Beilstein journal of nanotechnology vol. 5 (2014): 1312-9. doi: https://doi.org/10.3762/bjnano.5.144
Castillo PM, de la Mata M, Casula MF, Sánchez-Alcázar JA, Zaderenko AP. PEGylated versus non-PEGylated magnetic nanoparticles as camptothecin delivery system. Beilstein J Nanotechnol. 2014 Aug 19;5:1312-9. doi: 10.3762/bjnano.5.144. eCollection 2014. PMID: 25247114; PMCID: PMC4168894.
Copy Download .nbib Format: NLM
Share it on

Beilstein J Nanotechnol. 2014 Aug 19;5:1312-9. doi: 10.3762/bjnano.5.144. eCollection 2014.

PEGylated versus non-PEGylated magnetic nanoparticles as camptothecin delivery system.

Beilstein journal of nanotechnology

Paula M Castillo, Mario de la Mata, Maria F Casula, José A Sánchez-Alcázar, Ana P Zaderenko

Affiliations

  1. INSTM and Dipartimento di Scienze Chimiche e Geologiche. Università di Cagliari, Italy ; Departamento de Sistemas Físicos, Químicos y Naturales. Universidad Pablo de Olavide, Sevilla, Spain.
  2. Centro Andaluz de Biología del Desarrollo (CABD-CSIC-Universidad Pablo de Olavide), Sevilla, Spain.
  3. INSTM and Dipartimento di Scienze Chimiche e Geologiche. Università di Cagliari, Italy.
  4. Departamento de Sistemas Físicos, Químicos y Naturales. Universidad Pablo de Olavide, Sevilla, Spain.

PMID: 25247114 PMCID: PMC4168894 DOI: 10.3762/bjnano.5.144

Abstract

Camptothecin (CPT; (S)-(+)-4-ethyl-4-hydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14-(4H,12H)-dione) is a highly cytotoxic natural alkaloid that has not yet found use as chemotherapeutic agent due to its poor water-solubility and chemical instability and, as a consequence, no effective administration means have been designed. In this work, camptothecin has been successfully loaded into iron oxide superparamagnetic nanoparticles with an average size of 14 nm. It was found that surface modification of the nanoparticles by polyethylene glycol enables loading a large amount of camptothecin. While the unloaded nanoparticles do not induce apoptosis in the H460 lung cancer cell line, the camptothecin-loaded nanoparticle formulations exhibit remarkable pro-apoptotic activity. These results indicate that camptothecin retains its biological activity after loading onto the magnetic nanoparticles. The proposed materials represent novel materials based on naturally occurring bioactive molecules loaded onto nanoparticles to be used as chemotherapeutic formulations. The procedure seems apt to be extended to other active molecules extracted from natural products. In addition, these materials offer the potential of being further implemented for combined imaging and therapeutics, as magnetic nanoparticles are known to be multifunctional tools for biomedicine.

Keywords: camptothecin; cancer therapy; iron oxide superparamagnetic nanoparticles; polyethylene glycol

References

  1. Int J Mol Sci. 2011;12(7):4237-49 - PubMed
  2. Eur J Pharm Sci. 2002 Mar;15(2):163-70 - PubMed
  3. Int J Pharm. 2013 May 1;448(1):221-30 - PubMed
  4. Int J Pharm. 2004 Oct 13;284(1-2):61-8 - PubMed
  5. Biochim Biophys Acta. 1998 Oct 1;1400(1-3):107-19 - PubMed
  6. Adv Drug Deliv Rev. 2010 Aug 30;62(11):1064-79 - PubMed
  7. J Hazard Mater. 2011 Sep 15;192(3):1539-47 - PubMed
  8. Cancer Chemother Pharmacol. 2009 Jan;63(2):363-70 - PubMed
  9. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2013 Mar-Apr;5(2):130-8 - PubMed
  10. Int J Pharm. 2011 Jan 17;403(1-2):201-6 - PubMed
  11. J Drug Target. 2013 Feb;21(2):107-25 - PubMed
  12. Mater Res Bull. 2009 Jun;34(6):415-421 - PubMed
  13. Mol Pharm. 2010 Dec 6;7(6):1921-9 - PubMed
  14. Biol Chem. 2012 Nov;393(11):1327-40 - PubMed
  15. J Clin Oncol. 2003 Jan 1;21(1):148-57 - PubMed
  16. Chem Soc Rev. 2012 Jun 7;41(11):4306-34 - PubMed
  17. Cell Death Dis. 2013 Mar 07;4:e527 - PubMed
  18. Adv Drug Deliv Rev. 2011 Jan-Feb;63(1-2):24-46 - PubMed
  19. Colloids Surf B Biointerfaces. 2014 May 1;117:406-13 - PubMed
  20. Biomacromolecules. 2006 Nov;7(11):3132-8 - PubMed
  21. Ann Oncol. 1997 Sep;8(9):837-55 - PubMed
  22. Curr Med Chem. 2006;13(17):2021-39 - PubMed
  23. Small. 2012 Dec 7;8(23):3573-8 - PubMed
  24. Int J Mol Sci. 2012;13(5):5554-70 - PubMed
  25. Nanomedicine (Lond). 2009 Dec;4(8):919-30 - PubMed
  26. ChemMedChem. 2009 Jun;4(6):988-97 - PubMed
  27. Anticancer Drug Des. 1998 Jul;13(5):453-61 - PubMed
  28. Adv Drug Deliv Rev. 2004 Sep 22;56(11):1649-59 - PubMed
  29. J Phys Chem B. 2012 Jun 21;116(24):7334-41 - PubMed
  30. J Ethnopharmacol. 1996 Apr;51(1-3):239-53; discussion 253-4 - PubMed
  31. Int J Pharm. 2006 Jan 3;307(1):93-102 - PubMed
  32. Biomaterials. 2008 Feb;29(4):487-96 - PubMed
  33. Int J Pharm. 2012 Dec 15;439(1-2):49-62 - PubMed
  34. Invest New Drugs. 2013 Aug;31(4):986-1000 - PubMed
  35. J Colloid Interface Sci. 2011 May 1;357(1):50-5 - PubMed
  36. Cancer Treat Rev. 2008 Nov;34(7):592-602 - PubMed

Publication Types